3. How comprehensive can we be in the economic assessment of vaccines?

References

• Standaert B, Rappuoli R. The building blocks for a health economic assessment. J Market Access Health Policy. 2017;5:1335162.
   Google Scholar
• Standaert B, Rappuoli R. How is the economic assessment of vaccines performed today? J Market Access Health Policy. 2017;5:1335163.
   Google Scholar
• Ricciardi W, Toumi M. National immunization therapeutic advisory group: it is time for experience sharing and best practice learning. J Mark Access Health Policy. 2015;3:29276.
   Google Scholar
• Standaert B. Are changes occurring in the perceived value of vaccines? Belgian J Paediatr. 2016;18(4):1–16.
   Google Scholar
• Philip R, Shapiro M, Paterson P, et al. Is it time for vaccination to “Go Viral”? Pediatr Infect Dis J. 2016;35(12):1343–1349.
   PubMed Web of Science ®Google Scholar
• Marlow LA, Waller J, Wardle J. The impact of human papillomavirus information on perceived risk of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(2):373–376.
   Web of Science ®Google Scholar
• Waller J, Marlow LA, Wardle J. Mothers’ attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1257–1261.
   PubMed Web of Science ®Google Scholar
• Oteng B, Marra F, Lynd LD, et al. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sex Transm Infect. 2011;87(1):52–57.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Wassil J, Bonefeld L, et al. Cost effectiveness has its place, but so does common sense. BMJ. 2014;349:g6759.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
   PubMed Web of Science ®Google Scholar
• Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol. 2010;118(1 Suppl):S2–S7.
   Google Scholar
• Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140–146.
   PubMed Web of Science ®Google Scholar
• Bärnighausen T, Berkley S. Reassessing the value of vaccines. Lancet. 2014;2(5):e251–e2.
   Web of Science ®Google Scholar
• Remy V, Largeron N, Quilici S, et al. The economic value of vacciantion: why prevention is wealth. J Mark Access Health Policy. 2015;3. DOI:10.3402/jmahp.v3.29284.
   Google Scholar
• WHO. Immunization supply chain and logistics 2016. [ updated 2016; Cited 2017 Apr 24]. Available from: www.who.int/immunization/programmes_systems/supply_chain/en/
   Google Scholar
• Clements BJ, Coady D, Gupta S. Economics of public health care reform in advanced and emerging economies. 1st ed. Washington, (DC): International Monetary Fund, Publication Services; 2012.
   Google Scholar
• Arora S. On epidemiologic and economic transitions: a historical view. In: Lopez-Casasnovas G, Rivera B, Currais L, editors. Health and economic growth. 1st ed. Cambridge (MA): MIT; 2005. p. 197–238.
   Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71–76.
   PubMed Web of Science ®Google Scholar
• Kotsopoulos N, Connolly MP, Postma MJ, et al. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine. 2013;31(46):5430–5434.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. 2012;30(8):681–695.
   Web of Science ®Google Scholar
• Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30(4):337–353.
   Web of Science ®Google Scholar
• Standaert B, Curran D, Postma J. Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Allocation. 2014;12(1):3.
   Web of Science ®Google Scholar
• Bala MV, Zarkin GA, Mauskopf JA. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. Value Health. 2002;5(4):338–346.
   Web of Science ®Google Scholar
• Baggaley R, Godfrey-Faussett P, Msiska R, et al. Impact of HIV infection on Zambian businesses. BMJ. 1994;309(6968):1549–1550.
   Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356–2359.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34(3):227–244.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R, Png M, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. The global burden of disease. Switzerland: WHO; 2008.
   Google Scholar
• Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J. 2008;27(1):S20–S7.
   Web of Science ®Google Scholar
• Huppertz HI, Forster J, Heininger U, et al. The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila). 2008;47(4):363–371.
   PubMed Web of Science ®Google Scholar
• Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11(3):471–484.
   PubMedGoogle Scholar
• Topachevskyi O, Standaert B, Van Bellinghen LA, et al. Can a Multi-Criteria Decision (MCD) optimisation model help decision makers in the optimal selection of vaccines when expanding their universal mass vaccination programme? The case of Poland. Value Health. 2013;16(7):A615.
   Web of Science ®Google Scholar
• Ethgen O, Standaert B. Population-versus cohort-based modelling approaches. Pharmacoeconomics. 2012;30(3):171–181.
   PubMed Web of Science ®Google Scholar
• Parez N, Giaquinto C, Du RC, et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis. 2014;14(5):416–425.
   Web of Science ®Google Scholar
• Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine. 2009;27(44):6121–6128.
   PubMed Web of Science ®Google Scholar
• Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Allocation. 2006;4(14):1–9.
   Google Scholar
• Marsh K, Lanitis T, Neasham D, et al. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics. 2014;32(4):345–365.
   PubMed Web of Science ®Google Scholar
• Standaert B, Ethgen O, Emerson R, et al. Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn? Adv Ther. 2014;31(10):1095–1108.
   Web of Science ®Google Scholar
• Standaert B, Strens D, Alwan A, et al. Medium- to long-term impact of rotavirus vaccination on hospital care in belgium: a 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). Infect Dis Ther. 2016;5(1):31–44.
   PubMed Web of Science ®Google Scholar
• Standaert B, Parez N, Tehard B, et al. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy. 2008;6(4):199–216.
   Google Scholar
• Dort T, Schecroun N, Standaert B. Improving the quality of care in paediatric hospital environment by optimizing budget allocation between investment in vaccination and future institutional development. Value Health. 2016;19(3):A106.
   Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14(3):245–252.
   PubMed Web of Science ®Google Scholar
• Standaert B, Strens D, Li X, et al. The sustained rotavirus vaccination impact on nosocomial infection, duration of hospital stay, and age: the RotaBIS study (2005-2012). Infect Dis Ther. 2016;5(4):509–524.
   PubMed Web of Science ®Google Scholar
• Thomas SL, Walker JL, Fenty J, et al. Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted. Vaccine. 2016;35(4):680–686.
   Web of Science ®Google Scholar
• Standaert B, Alwan A, Strens D, et al. Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: an evaluation study in Belgium. Hum Vaccin Immunother. 2015;11(9):2266–2273.
   PubMed Web of Science ®Google Scholar
• Standaert B, Van de Mieroop E, Nelen V. Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis. BMJ Open. 2015;5(6):e007453.
   PubMed Web of Science ®Google Scholar
• Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine. 2010;28(18):3118–3126.
   Web of Science ®Google Scholar
• Martin A, Batty A, Roberts JA, et al. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine. 2009;27(33):4520–4528.
   Web of Science ®Google Scholar
• Madhavan G, Sangha K, Phelps C, et al. Ranking Vaccines, a prioritization framework. Washington (DC): The National Academies Press; 2012.
   Google Scholar